NOVO NORDISK A S
NONOFDrugs in Pipeline
87
Phase 3 Programs
61
Upcoming Catalysts
6
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
6 upcoming, 1 past
human insulin
Diabetes
eptacog alfa (activated)
Acquired Bleeding Disorder
estradiol, 10 mcg
Menopause
Norditropin®
SGA, Turner Syndrome, Noonan Syndrome, ISS
biphasic insulin aspart 50
Diabetes
estradiol, 25 mcg
Menopause
semaglutide 2.4 mg
Obesity
activated recombinant human factor VII
Acquired Bleeding Disorder
human soluble insulin
Diabetes
Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
Vulvovaginal Atrophy
Recombinant Activated Factor VII (rFVIIa)
Intracerebral Hemorrhage
insulin
Diabetes
insulin glargine
Diabetes
Metformin on top of intensive insulin therapy
Type 2 Diabetes Mellitus
IDegLira
Diabetes Mellitus
10% Hemohes® (10% Hydroxyethyl starch)
Severe Sepsis
Insulin infusion with a goal
Cardiac Surgical Procedures
Etavopivat Tablets Low dose
Sickle Cell Disease
Semaglutide 2.4mg
Obesity
nexium
Type 2 Diabetes
Recombinant Factor VIIa
Intracerebral Hemorrhage
SOMATROPINE* : Norditropine® simplexx®
Anorexia Nervosa
Liraglutide Pen Injector [Saxenda]
Pre Diabetes
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
Diabetes Mellitus, Type 1
NovoLog
Type 2 Diabetes Treated With Insulin
Insulin Asparte
Cystic Fibrosis
Zenagamtide
Type 2 Diabetes
Repaglinide
Cystic Fibrosis
Cagrilintide
Obesity
insulin aspart
Diabetes
liraglutide
Diabetes
insulin degludec/liraglutide
Diabetes
Mim8
Haemophilia A With or Without Inhibitors
rosiglitazone
Diabetes
insulin degludec/insulin aspart
Diabetes
Ziltivekimab
Cardiovascular Risk
biphasic insulin aspart
Diabetes
Insulin Icodec
Diabetes Mellitus, Type 2
insulin degludec
Diabetes
Semaglutide
Diabetes Mellitus, Type 2
catridecacog
Congenital Bleeding Disorder
Turoctocog alfa pegol
Congenital Bleeding Disorder
Somapacitan
Growth Hormone Deficiency in Children
insulin detemir
Diabetes
biphasic human insulin
Diabetes
biphasic insulin aspart 30
Diabetes
NPH insulin
Diabetes Mellitus, Type 1
Faster-acting insulin aspart
Diabetes
insulin NPH
Diabetes
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Nonacog beta pegol
Haemophilia B
biphasic insulin aspart 70
Diabetes
turoctocog alfa
Congenital Bleeding Disorder
Oral semaglutide
Obesity
somatropin
Growth Hormone Disorder
DCR-PHXC
Primary Hyperoxaluria Type 1
exenatide
Diabetes
IcoSema
Diabetes Mellitus, Type 2
Concizumab
Haemophilia A With Inhibitors
NNC0487-0111
Obesity
CagriSema (Cagrilintide B and Semaglutide I)
Diabetes Mellitus, Type 2
recombinant interleukin-21
Cancer
Everolimus (Afinitor®)
Postmenopausal Women
vatreptacog alfa (activated)
Congenital Bleeding Disorder
Mixed Meal Tolerance Test with paracetamol
Type 1 Diabetes Mellitus
NNC0519-0130
Obesity
Dobutamine
Acute Myocardial Infarction
Semaglutide Pen Injector
NAFLD
Semaglutide (SEMA)
Nonalcoholic Steatohepatitis
GlucoNorm
Type 2 Diabetes
NNC0365-3769 (Mim8)
Healthy Volunteers
NNC126-0083
Growth Hormone Disorder
Actrapid HM
Diabetes, Type I
Norditropin SimpleXx (growth hormone)
Growth Hormone Deficiency
CDR132L
Heart Failure
NNC0662-0419
Diabetes Mellitus, Type 2
autologous stored platelets
Bleeding
NNC0114-0006
Inflammation
Insulin glargine U100
Diabetes Mellitus, Type 2
Firsocostat
Nonalcoholic Steatohepatitis
intensive insulin therapy to maintain normoglycemia
Critical Illness
Growth Hormone
TBI (Traumatic Brain Injury)
inhaled human insulin
Diabetes
Regular Human Insulin
Type 2 Diabetes Mellitus
EX1000
Diabetes
Etavopivat
Sickle Cell Disease
Dasatinib 100 Mg Oral Tablet
Osteopenia, Osteoporosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
human insulin | Phase 3 | Diabetes | - | - |
eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder | - | - |
estradiol, 10 mcg | Phase 3 | Menopause | - | - |
Norditropin® | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
estradiol, 25 mcg | Phase 3 | Menopause | - | - |
semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
human soluble insulin | Phase 3 | Diabetes | - | - |
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] | Phase 3 | Vulvovaginal Atrophy | - | - |
Recombinant Activated Factor VII (rFVIIa) | Phase 3 | Intracerebral Hemorrhage | - | - |
insulin | Phase 3 | Diabetes | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
Metformin on top of intensive insulin therapy | Phase 3 | Type 2 Diabetes Mellitus | - | - |
IDegLira | Phase 3 | Diabetes Mellitus | - | - |
10% Hemohes® (10% Hydroxyethyl starch) | Phase 3 | Severe Sepsis | - | - |
Insulin infusion with a goal | Phase 3 | Cardiac Surgical Procedures | - | - |
Etavopivat Tablets Low dose | Phase 3 | Sickle Cell Disease | - | - |
Semaglutide 2.4mg | Phase 3 | Obesity | - | - |
nexium | Phase 3 | Type 2 Diabetes | - | - |
Recombinant Factor VIIa | Phase 3 | Intracerebral Hemorrhage | - | - |
SOMATROPINE* : Norditropine® simplexx® | Phase 3 | Anorexia Nervosa | - | - |
Liraglutide Pen Injector [Saxenda] | Phase 3 | Pre Diabetes | - | - |
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
NovoLog | Phase 3 | Type 2 Diabetes Treated With Insulin | - | - |
Insulin Asparte | Phase 3 | Cystic Fibrosis | - | - |
Zenagamtide | Phase 3 | Type 2 Diabetes | - | - |
Repaglinide | Phase 3 | Cystic Fibrosis | - | - |
Cagrilintide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A With or Without Inhibitors | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
Ziltivekimab | Phase 3 | Cardiovascular Risk | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
insulin degludec | Phase 3 | Diabetes | - | - |
Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
Turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
Somapacitan | Phase 3 | Growth Hormone Deficiency in Children | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
NPH insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Nonacog beta pegol | Phase 3 | Haemophilia B | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
turoctocog alfa | Phase 3 | Congenital Bleeding Disorder | - | - |
Oral semaglutide | Phase 3 | Obesity | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 | - | - |
exenatide | Phase 3 | Diabetes | - | - |
IcoSema | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Concizumab | Phase 3 | Haemophilia A With Inhibitors | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
recombinant interleukin-21 | Phase 2 | Cancer | - | - |
Everolimus (Afinitor®) | Phase 2 | Postmenopausal Women | - | - |
vatreptacog alfa (activated) | Phase 2 | Congenital Bleeding Disorder | - | - |
Mixed Meal Tolerance Test with paracetamol | Phase 2 | Type 1 Diabetes Mellitus | - | - |
NNC0519-0130 | Phase 2 | Obesity | - | - |
Dobutamine | Phase 2 | Acute Myocardial Infarction | - | - |
Semaglutide Pen Injector | Phase 2 | NAFLD | - | - |
Semaglutide (SEMA) | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
GlucoNorm | Phase 2 | Type 2 Diabetes | - | - |
NNC0365-3769 (Mim8) | Phase 2 | Healthy Volunteers | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
Actrapid HM | Phase 2 | Diabetes, Type I | - | - |
Norditropin SimpleXx (growth hormone) | Phase 2 | Growth Hormone Deficiency | - | - |
CDR132L | Phase 2 | Heart Failure | - | - |
NNC0662-0419 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
autologous stored platelets | Phase 2 | Bleeding | - | - |
NNC0114-0006 | Phase 2 | Inflammation | - | - |
Insulin glargine U100 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
intensive insulin therapy to maintain normoglycemia | Phase 2 | Critical Illness | - | - |
Growth Hormone | Phase 2 | TBI (Traumatic Brain Injury) | - | - |
inhaled human insulin | Phase 2 | Diabetes | - | - |
Regular Human Insulin | Phase 2 | Type 2 Diabetes Mellitus | - | - |
EX1000 | Phase 2 | Diabetes | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
Dasatinib 100 Mg Oral Tablet | Phase 2 | Osteopenia, Osteoporosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NOVO NORDISK A S's drug pipeline?→
CatalystAlert tracks 87 drug candidates in NOVO NORDISK A S's (NONOF) pipeline across Phase 3, Phase 2. Its lead program is human insulin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NOVO NORDISK A S's next FDA catalyst?→
NOVO NORDISK A S's (NONOF) next tracked catalyst is a Phase 2 expected September 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NONOF biotech catalysts?→
Add NONOF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NOVO NORDISK A S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.